Search

Your search keyword '"Etemadifar M"' showing total 130 results

Search Constraints

Start Over You searched for: Author "Etemadifar M" Remove constraint Author: "Etemadifar M" Topic multiple sclerosis Remove constraint Topic: multiple sclerosis
130 results on '"Etemadifar M"'

Search Results

1. Anti-CD20 therapies for pediatric-onset multiple sclerosis: A systematic review.

2. A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.

3. Span of spleen is associated with disability status in multiple sclerosis: a cross-sectional abdominopelvic ultrasonography study.

4. The diagnostic performance of AI-based algorithms to discriminate between NMOSD and MS using MRI features: A systematic review and meta-analysis.

5. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.

6. Balance rehabilitation for patients with Multiple Sclerosis using a Kinect®-based virtual training program.

7. Human exposure to dust and heavy metals in industrial regions and its relationship with the prevalence of multiple sclerosis disease.

8. Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity.

9. Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine.

10. Neuromuscular Electrical Stimulation in Conjunction with Conventional Swallowing Therapy in the Treatment of Dysphagia Caused by Multiple Sclerosis: A Single-Case Experimental Design.

11. Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse.

12. Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis.

13. Diagnosis and classification of optic neuritis.

14. Facial involvement in multiple sclerosis.

15. Revisiting the antiviral theory to explain interferon-beta's effectiveness for relapsing multiple sclerosis.

16. Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis.

17. Barriers to quality of life in patients with multiple sclerosis: a qualitative study.

18. Centrally-located transverse myelitis would facilitate the differentiation of NMOSD and MOG-AD from MS.

19. Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study.

20. Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors.

21. Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis.

22. SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine.

23. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient.

24. Evaluation of matrix metalloproteinase-9 plasma levels in untreated new Relapsing-remitting multiple sclerosis patients and their first-degree family.

25. Multiple sclerosis epidemiology in Asia and Oceania; A systematic review and meta-analysis.

26. The effect of counseling based on the PLISSIT model on sexual quality of life of married women with multiple sclerosis referring to MS center in 2019: a randomized, controlled trial.

27. COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?

28. Explaining the facilitators of quality of life in patients with multiple sclerosis: a qualitative study.

29. The Effect of IFN-β Treatment on Plasma Levels of BDNF and IL-6 in Relapsing-Remitting Multiple Sclerosis Patients.

30. MRI signs of CNS demyelinating diseases.

31. The effect of fampridine on the risk of seizure in patients with multiple sclerosis.

32. Evaluating the effectiveness of cognitive rehabilitation on everyday memory in multiple sclerosis patients.

33. Incidence and prevalence of multiple sclerosis in persian gulf area: A systematic review and meta-analysis.

34. The higher prevalence of multiple sclerosis among Iranian Georgians; new clues to the role of genetic factors.

35. Joint Application of Magnetic Resonance Imaging and Biochemical Biomarkers in Diagnosis of Multiple Sclerosis.

36. Complete horizontal gaze palsy due to bilateral paramedian pontine reticular formation involvement as a presentation of multiple sclerosis: a case report.

37. Anti-HSV-2 antibody in patients with MS and NMO.

38. Acute vision loss in multiple sclerosis: Optic neuritis or central serous chorioretinopathy?

39. Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: Clinical course and treatment outcome.

42. Memory rehabilitation for the working memory of patients with multiple sclerosis (MS).

43. Investigation of ERG Gene Expression in Iranian Patients with Multiple Sclerosis.

44. Patient preferences for Interferon-beta in Iran: A discrete choice experiment.

45. Serum level of interleukin 36 in patients with multiple sclerosis.

46. CD25 gene polymorphism and multiple sclerosis.

47. Statistical support for Sema3A and multiple sclerosis.

48. Cytomegalovirus and varicella zoster virus seropositivity of Iranian patients with multiple sclerosis: A population-based study.

49. Multiple sclerosis among Afghan immigrants in Isfahan, Iran.

50. Prevalence of multiple sclerosis in Iranian emigrants: review of the evidence.

Catalog

Books, media, physical & digital resources